Search
Moderna Inc
MRNAAdd to Watchlist
54.350USD
+5.810+11.97%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
21.57BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+11.97%
5 Days
+19.79%
1 Month
+4.32%
6 Months
+121.48%
Year to Date
+84.30%
1 Year
+122.93%
TradingKey Stock Score of Moderna Inc
Currency: USD Updated: 2026-05-08Key Insights
Moderna Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 48.06.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Moderna Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
1°C
Very Low
Very High
Neutral
Moderna Inc Highlights
StrengthsRisks
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Fairly Valued
The company’s latest PE is -6.68, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 313.36M shares, increasing 2.74% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.26K shares of this stock.
Analyst Rating
Based on
24
analysts
Hold
Current Rating
48.062
Target Price
+1.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Moderna Inc Info
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Ticker SymbolMRNA
CompanyModerna Inc
CEOBancel (Stephane)
Websitehttps://www.modernatx.com/
Related Instruments
-2.72%
-0.53%
-0.57%
+0.44%
+0.18%
-0.82%
+0.79%
-2.04%
+0.59%
-3.02%
-0.16%
+1.13%
+0.30%
-0.18%
-2.47%
+0.82%
0.00%
-1.08%
-0.65%
-0.88%Popular Instruments
92.193
-2.977 (-3.13%)
293.320
+5.880 (+2.05%)
215.200
+3.700 (+1.75%)
4714.280
+29.030 (+0.62%)
480.000
+16.090 (+3.47%)
1562.340
+222.380 (+16.60%)
746.810
+100.180 (+15.49%)
400.800
+2.810 (+0.71%)
80766.550
+663.460 (+0.83%)
428.350
+16.560 (+4.02%)
